News | May 27, 2025
Aurobindo Pharma Q4 PAT falls marginally to Rs. 903 Cr
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
For over 13 years, Star Imaging has pioneered the introduction of next-generation radiology technologies in Pune
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
She has held senior positions at Coca-Cola in China and PepsiCo in India
Scores highest PAT of Rs. 118 crore in FY25
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
Subscribe To Our Newsletter & Stay Updated
